Immuron (NASDAQ:IMRN) has secured exclusive U.S. distribution rights for digestive health product PROIBS through an agreement with Calmino group AB, expanding its commercial portfolio after launching the product in Australia during FY26.
Key Investor Takeaways
- Immuron (NASDAQ:IMRN) plans a U.S. PROIBS launch after signing an exclusive distribution agreement with developer Calmino group AB.
- The agreement expands Immuron’s digestive health portfolio beyond Travelan and builds on the PROIBS rollout in Australia during FY26.
- Immuron cited a $4.16 billion overall U.S. digestive and gut health supplement market, although PROIBS will target only a subset of that market.
- Calmino’s usability study involving 1,003 users found PROIBS helpful for 94%, while 91% reported an improvement in daily life.
- The expansion adds another commercial product to Immuron’s U.S. strategy, although the announcement does not provide launch timing or financial terms for the distribution agreement.
Why IMRN Stock Is in Focus
Immuron has executed an exclusive agreement with Sweden-based Calmino group AB to distribute PROIBS in the United States, extending a partnership that already covers Australia.
PROIBS is a medical device used for abdominal pain, bloating and unsettled bowel movements, including diarrhoea and constipation. It contains AVH200, derived from Aloe barbadensis Mill, with gel-forming components designed to support the intestinal mucosal barrier.
Calmino’s usability study of 1,003 users reported that PROIBS was helpful for 94% of participants, with 91% experiencing an improvement in daily life and 98% saying they would recommend the product.
Immuron did not disclose the financial terms of the U.S. distribution agreement or provide a specific timetable for the launch.
Why This Matters for Investors
The U.S. PROIBS launch broadens Immuron’s commercial exposure within digestive health and supports management’s strategy of developing a portfolio of products in the category.
The company specifically linked the move to what it described as rapid U.S. sales growth for Travelan. Adding PROIBS could therefore allow Immuron to build on its existing commercial presence rather than relying on a single digestive health product.
The size of the broader market also provides context for the opportunity. Immuron cited a $4.16 billion U.S. digestive and gut health supplement market, while making clear that PROIBS is targeting only a subset.
For investors, the key question now shifts from securing distribution rights to commercial execution. The agreement establishes a route into the U.S. market, but the release does not quantify expected PROIBS revenue, launch costs or the potential financial contribution from the product.
What to Watch Next
Investors can watch for a confirmed U.S. launch timetable, details of Immuron’s commercial strategy for PROIBS and indications of early market uptake. Future updates showing how PROIBS contributes alongside Travelan could provide a clearer view of whether Immuron’s broader digestive health portfolio strategy is gaining traction.